Cardiometabolic & kidneyDiagnostic or prognostic study
Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme
- Risk prediction model development and validation study
- pooled patient data set (FIDELITY)
- derivation in placebo arm, validation in finerenone arm
- integer risk score
Study context
- Population
- Patients with CKD and T2DM (FIDELITY pooled data)
- Comparison
- Low risk vs Intermediate risk vs High risk
- Outcome
- New-onset hyperkalaemia (serum potassium >5.5 mmol/L)
Performance
As reported in the abstract
New-onset hyperkalaemia by risk category, placebo
- Seven baseline covariates independently associated with new-onset hyperkalaemia (serum potassium >4.5 mmol/L, prior hyperkalaemia, no SGLT2 inhibitor use, urine albumin-to-creatinine ratio >1000 mg/g, haemoglobin <12 g/dL, no thiazide-type diuretic use, eGFR <45 mL/min/1.73 m²)
- 7
- Integer score range
- 0 to 12 points
Further findings
CV and kidney composites, finerenone vs placebo, by hyperkalaemia risk
- Finerenone reduced CV and kidney events vs placebo irrespective of hyperkalaemia risk
Original publication
Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme. Eur Heart J. Published 22 April 2025. doi:10.1093/eurheartj/ehaf258
Summarised from the published abstract; every number is checked against it